Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IFRX | PRESS-RELEASE | bullish | 8/10 | InflaRx N.V. announced that Phase 3 data for its drug vilobelimab in pyoderma gangrenosum (PG) will be presented at the | Mar 18, 2026 |
| FENC | PRESS-RELEASE | neutral | 3/10 | Fennec Pharmaceuticals announced it will release its full year and fourth quarter 2025 financial results on March 24, 20 | Mar 18, 2026 |
| HROW | PRESS-RELEASE | neutral | 3/10 | Harrow, Inc. announced that three scientific abstracts featuring its ophthalmic products VEVYE® and ILEVRO® have been ac | Mar 18, 2026 |
| ARVN | PRESS-RELEASE | bullish | 8/10 | Arvinas presented positive Phase 1 data for ARV-102, showing approximately 50% or greater reduction of LRRK2 in cerebros | Mar 18, 2026 |
| ACRS | PRESS-RELEASE | neutral | 5/10 | Aclaris Therapeutics announced completion of patient enrollment in its Phase 2 trial of bosakitug (ATI-045), an anti-TSL | Mar 18, 2026 |
| OVID | PRESS-RELEASE | mixed | 6/10 | Ovid Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a $9.7 million net income in Q4 drive | Mar 18, 2026 |
| XOMA | PRESS-RELEASE | bullish | 8/10 | XOMA Royalty Corporation reported strong full-year 2025 financial results with revenue up 83% YoY to $52.1 million and a | Mar 18, 2026 |
| OVID | PRESS-RELEASE | neutral | 5/10 | Ovid Therapeutics announced a $60.0 million PIPE financing through the sale of common stock and pre-funded warrants, pri | Mar 18, 2026 |
| CTMX | PRESS-RELEASE | neutral | 6/10 | CytomX Therapeutics priced a public offering of 45,990,567 shares and pre-funded warrants for 1,179,245 shares at $5.30 | Mar 17, 2026 |
| SABS | PRESS-RELEASE | bearish | 6/10 | SAB Biotherapeutics (SABS) announced the pricing of a public offering, selling 19.3 million shares at $3.85 and pre-fund | Mar 17, 2026 |
| AAPG | PRESS-RELEASE | neutral | 4/10 | Ascentage Pharma announced that four preclinical abstracts from its drug pipeline, including data on olverembatinib, APG | Mar 17, 2026 |
| ZYME | PRESS-RELEASE | neutral | 3/10 | Zymeworks announced the acceptance of an oral presentation and six abstracts from its R&D portfolio for presentation at | Mar 17, 2026 |
| SLXN | PRESS-RELEASE | mixed | 6/10 | Silexion Therapeutics reported financial results for 2025, showing a reduced annual net loss of $11.9 million compared t | Mar 17, 2026 |
| AVBP | PRESS-RELEASE | neutral | 4/10 | ArriVent BioPharma presented preclinical data at AACR 2026 for two pipeline candidates: firmonertinib, an EGFR inhibitor | Mar 17, 2026 |
| CATX | PRESS-RELEASE | neutral | 4/10 | Perspective Therapeutics announced that updated clinical data from its [212Pb]VMT-α-NET program for neuroendocrine tumor | Mar 17, 2026 |
| XLO | PRESS-RELEASE | neutral | 4/10 | Xilio Therapeutics announced an upcoming poster presentation at the AACR Annual Meeting in April 2026, detailing preclin | Mar 17, 2026 |
| TNXP | PRESS-RELEASE | neutral | 3/10 | Tonix Pharmaceuticals announced upcoming presentations at the AACR Annual Meeting 2026 on its preclinical immuno-oncolog | Mar 17, 2026 |
| ADAG | PRESS-RELEASE | neutral | 5/10 | Adagene Inc. announced that its lead candidate, muzastotug (ADG126), will be featured in two poster presentations at the | Mar 17, 2026 |
| AKTX | PRESS-RELEASE | neutral | 4/10 | Akari Therapeutics is executing a 1-for-40 reverse split of its ADS ratio, reducing the number of ordinary shares per AD | Mar 17, 2026 |
| IMA | PRESS-RELEASE | neutral | 3/10 | ImageneBio granted inducement equity awards totaling 38,442 RSUs and 43,000 NSOs to two new employees, as permitted unde | Mar 17, 2026 |
| EVAX | PRESS-RELEASE | neutral | 4/10 | Evaxion announced two abstracts accepted for presentation at the AACR Annual Meeting, featuring new biomarker and immuno | Mar 17, 2026 |
| IMCR | PRESS-RELEASE | neutral | 5/10 | Immunocore announced it will present five-year overall survival data from the KIMMTRAK Phase 3 trial in metastatic uveal | Mar 17, 2026 |
| SLS | PRESS-RELEASE | mixed | 5/10 | SELLAS Life Sciences announced preclinical data for its CDK9 inhibitor SLS009 (tambiciclib) showing potent apoptosis ind | Mar 17, 2026 |
| TRVI | PRESS-RELEASE | mixed | 6/10 | Trevi Therapeutics reported fourth quarter and full-year 2025 financial results, highlighted by a reduced net loss and $ | Mar 17, 2026 |
| SNYR | PRESS-RELEASE | neutral | 3/10 | Synergy CHC Corp. announced it will release its Q4 and full-year 2025 financial results on March 31, 2026, followed by a | Mar 17, 2026 |
| LGVN | PRESS-RELEASE | bearish | 7/10 | Longeveron reported a 50% year-over-year revenue decline for 2025, driven by lower clinical trial and contract manufactu | Mar 17, 2026 |
| MYGN | PRESS-RELEASE | bullish | 8/10 | Myriad Genetics announced FDA approval of its MyChoice® CDx Test as the companion diagnostic for GSK's Zejula (niraparib | Mar 17, 2026 |
| SABS | PRESS-RELEASE | bearish | 6/10 | SAB Biotherapeutics (SABS) has announced the commencement of an underwritten public offering of common stock and pre-fun | Mar 17, 2026 |
| CMND | PRESS-RELEASE | neutral | 4/10 | Clearmind Medicine announced the publication of six patents in Hong Kong covering proprietary combination therapies that | Mar 17, 2026 |
| ASND | PRESS-RELEASE | bullish | 7/10 | Ascendis Pharma announced positive Week 52 results from its Phase 2 New InsiGHTS trial, showing that once-weekly TransCo | Mar 17, 2026 |